// App-Quantinova.ai

5061 : Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC).

Researchers

Presenter

  • Eleni Efstathiou

Principal Investigators

  • Patricia Troncoso

  • Anh Hoang

  • Ina N. Prokhorova

  • Sijin Wen

  • Christopher Logothetis

  • Elsa Li Ning Tapia

  • John W. Davis

  • Mark Anton Titus

Medical Centers

  • West Virginia University School of Public Health, Morgantown, WV

  • The University of Texas MD Anderson Cancer Center, Houston, TXAlexandra General Hospital of Athens, Oncology Department, Department of Clinical Therapeutics, University of Athens, Athens, Greece

Locations

  • United States

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Leuprolide acetate

  • Enzalutamide

  • Prednisone

  • Androgen Tear

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved